Please select the option that best describes you:
Topics:
Gastrointestinal Cancers • Medical Oncology
Would you consider adding durvalumab to second-line chemotherapy for cholangiocarcinoma which progressed on gem/cis alone?
No actionable genetic alterations were identified for this patient. Would you consider FOLFOX + durva, or even single-agent durva?
Answer from: Medical Oncologist at Academic Institution
Yes. Data is needed, however, a scaffold approach maintaining durvalumab and adding different chemotherapies like NIFTY or FOLFOX as walls to the building frame of immunotherapy is appropriate and justified.
Sign in or Register to read more